Trial intelligence / Profile preview

Phase 1/2 open-label vimseltinib study in advanced tumors and tenosynovial giant cell tumor

NL-OMON59252Phase 2Active, not recruiting

Sponsor

Deciphera Pharmaceuticals

Start

May 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1